BioCryst tightens revenue guidance

 — Q3 2024 ORLADEYO net revenue of $116.3 million (+35.7 percent y-o-y) —

— Full-year 2024 ORLADEYO revenue guidance adjusted to $430-$435 million (top end of prior guidance range) —

— Company introduces full-year 2024 total product revenue guidance of $443-$448 million based on additional 2024 revenue from RAPIVAB —

— BCX17725 for Netherton syndrome advances into the clinic —

— Company generates GAAP operating profit of $7.7 million in third quarter ($24.9 million non-GAAP operating profit) —

https://www.globenewswire.com/news-release/2024/11/04/2973912/29446/en/BioCryst-Reports-Third-Quarter-2024-Financial-Results-and-Provides-Business-Update.html